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Abstract 
Introduction: Multiple Breath Washout (MBW) to measure Lung Clearance Index (LCI) is 
increasingly being used as a secondary endpoint in multicentre bronchiectasis studies. LCI 
data quality control or “over-reading” is resource intensive and the impact is unclear. 
Objectives:  To  assess  the  proportion  of  MBW  tests  deemed  unacceptable  with  over-
reading, and to assess the change in LCI (number of turnovers), LCI coeﬃcient of variation  
(CV%) and tidal volume (VT) CV% results after over-reading.  
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Methods:   Data were analysed from 250 MBW tests (from 98 adult bronchiectasis patients) 
collected as part of the Bronch-UK Clinimetrics study in 5 UK centres. Each MBW test was 
over-read  centrally  using  pre-deﬁned  criteria.  MBW  tests  with  <  2  technically  valid  and 
repeatable trials were deemed unacceptable to include in analysis. In accepted tests, values 
for LCI, LCI CV% and VT CV% before and after over-reading, were compared.  
Results:  Insuﬃcient data was collected in 10/250 tests. With over-reading, 30/240 (12%) 
were  deemed  unacceptable  to  include  in  analysis.  In  those  accepted  tests,  overall  the 
change in LCI, LCI CV% and VT CV% with over-reading was not statistically significant. 
When MBW new sites were compared to MBW expert sites, the change in LCI with over-
reading  was  signiﬁcantly greater  in  MBW  new sites  (p=0.047). Data  suggests  that over-
reading could be important up to at least 12 months post initiation of MBW activity. 
Conclusion:  MBW  over-reading  was  important  in  this  study  as  12%  of  tests  were 
considered unacceptable. Over-reading improved test result accuracy in sites new to MBW.  
 
Introduction 
Lung Clearance index (LCI) is the most commonly reported multiple breath washout (MBW) 
parameter. It has good clinimetric properties as an outcome measure and has been adopted 
as a surrogate endpoint in cystic ﬁbrosis (CF) clinical trials (1-4). There is an increasing body 
of evidence that forced expiratory volume in one second (FEV1) is insensitive to early lung 
disease, and the majority of clinical trials in bronchiectasis have been unable to demonstrate 
a  treatment  eﬀect  using  FEV1 (5,6).  This  highlights  the  need  for  other,  sensitive  and 
responsive  markers  of  lung  function  in  bronchiectasis.  LCI  is  being  used  in  multicentre 
bronchiectasis studies as it has been shown to have good intravisit repeatability with better 
sensitivity in detecting lung disease on CT scan compared to FEV1 (7-9). Much effort has 
been made to improve standardisation of MBW training, testing and analysis (10-14). 
Accurate estimation of LCI and other MBW parameters depends on correct operation of the 
device and appropriate analysis and interpretation of the collected data. Acquisition of good 
quality MBW data can be inﬂuenced by operator training, competence and experience in 
testing and reporting of the data.  
MBW test results from diﬀerent devices are not interchangeable and standardization 
of  the  device  used  is  required  in  multicenter  studies  (15).  However,  even  with 
standardization of the device, diﬀerences in software settings, patient interface dead space, 
breathing  pattern  protocols  and  operator  technical  expertise  can  all  impact  on  results 
(14,16,17).  Central  co-ordination and  data  quality control  or  “over-reading” service  could 
improve standardisation in testing and reporting of the data to a research quality standard in 
accordance with consensus statement guidance (10). 
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An  over-reading  protocol,  to  systematically  evaluate  MBW  measurements  for 
technical elements and stability of the breathing pattern, has been used in children with CF. 
The impact of the protocol on inter-observer agreement and reported MBW outcomes was 
assessed across 8 MBW operators from 4 institutions. Overall, use of the protocol resulted in 
improved inter-observer agreement but no change in reported MBW outcomes after over-
reading. In 50 MBW tests (25 healthy children and 25 children with CF), application of an 
over reading protocol resulted in the rejection of 16.6% for technical reasons and a further 
10.7% due to inappropriate breathing pattern (11). Over-reading in longitudinal studies was 
highlighted as important consideration, as the variability of the outcome within and between 
subjects will aﬀect interpretation. In a multicentre study of 183 CF patients and 136 healthy 
volunteers  from  8  centres,  24%  of  measurements  in  both  groups  were  excluded due  to 
quality issues (18). This study emphasised the importance of site training and a central over-
reading process in multicentre studies. More recently, central training and assessment of 
MBW tests in CF pre-school children and infants, reported high rates test success (91.8%) 
(19).  
 
These studies  highlight the  importance of  central  over-reading  for the accuracy  of  MBW 
measurements  in  the  multicentre  setting  in  CF.  However,  over-reading  of  MBW  data  is 
resource intensive and signiﬁcantly increases study costs. Currently there are no studies on 
the impact of central over-reading for MBW testing in the adult bronchiectasis population. In 
this  study,  we  hypothesise  that  a  central  over-reading  process  in  a  multicentre 
bronchiectasis study will improve MBW result accuracy. 
 
Aim  
To  determine  the  impact  of  central  MBW  over-reading  in  the  bronchiectasis  multicentre 
clinical  study  setting  using  data  collected  in  the  BRONCH-UK  Clinimetrics  study 
(ClinicalTrials.gov Identiﬁer: NCT02468271). The impact of site MBW experience, length of 
sites  current  MBW  testing  activity and  patient  clinical status  during  MBW  testing  on  the 
outcome  of  over-reading  was  also  assessed.  All  sites  completed  a  certiﬁcation  process 
before collecting MBW data in the study. 
 
Objectives 
•  To assess the proportion of MBW tests deemed unacceptable after over-reading. 
•  To  assess  the  change  in  LCI  (number  of  turnovers),  LCI  variability  (coeﬃcient  of 
variation [CV%]) and tidal volume (VT) variability (CV%) after over-reading. 
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•  To assess the change in LCI (no. turnovers), LCI CV% and VT CV% in MBW expert sites 
versus MBW new sites. 
•  To  assess the  change  in  LCI  (no. turnovers), LCI  CV%  and VT  CV%  in the ﬁrst  12 
months of site MBW study activity versus the remaining study period. 
•  To assess the change in LCI (no. turnovers), LCI CV% and VT CV% in clinically stable 
versus pulmonary exacerbation MBW tests. 
 
Methods 
The BRONCH-UK Clinimetrics study is a prospective cohort study to determine the utility of 
a  range  of  outcome  measures  including  LCI,  in  clinical  trials  in  bronchiectasis 
(https://www.bronch.ac.uk/clinimetrics-study;  ClinicalTrials.gov  Identiﬁer:  NCT02468271).  
During the study, patients performed a MBW test in up to 6 study visits over a 24 month 
period  (including  4  clinically  stable  and  2  exacerbation  study  visits).  A  pulmonary 
exacerbation was defined as an acute respiratory infection requiring oral or IV antibiotics in 
the  presence  of four abnormalities in  the following  nine  categories:  1.  increased sputum 
production;  2.  increased  dyspnoea;  3.  increased  cough;  4.  fever  >38oC;  5.  increased 
wheeze; 6. decreased exercise tolerance/malaise; 7. 10% decrease in FEV1 from baseline; 
8. new radiographic changes of a pulmonary process  9. changes in chest sounds {{1426 ;
O'Donnell,A.E. 1998}}. 
The study is currently on-going and data collected from November 2015 to July 2017 were 
used in this study. The data collected were from ﬁve UK sites, trained and certiﬁed in MBW 
testing in the bronchiectasis patient population. Three of the sites were previously naive to 
MBW  testing  (sites  2,  3,  4)  and  2  sites  were  MBW  expert  sites  (sites  1,  5).  During  a 
scheduled  research  study  visit,  a  Multiple  Breath  Nitrogen  Washout  (MBN2W)  test  was 
performed  using  the Ecomedics  Exhalyzer®  D  (Spiroware software  version  3.1.6)  and  a 
published Standard Operating Procedure (SOP) developed for CF by Jensen and working 
group  ( ).  MBW  was  carried  out  prior  to http://lab.research.sickkids.ca/ratjen/mbw-centre/
spirometry and patients were also instructed to withhold bronchodilators prior to the study 
visit (SABA were withheld for at least 4 hours; LABA for > 12 hours). There was no speciﬁc 
instruction regarding withholding of physiotherapy airway clearance. Patients performed at 
least 3 trials during which they breathed 100% oxygen during tidal breathing until N2 was 
washed out to <2.5% for at least 3 consecutive breaths. Sites followed quality control steps 
as  detailed  in  the  SOP  ( )  in  addition  to http://lab.research.sickkids.ca/ratjen/mbw-centre/
using quality control feedback provided by the Spiroware software (appendix 1). After the 
study visit, sites sent MBW data to the central over-reading facility in Belfast. Each test was 
assessed for validity and quality by a trained “over-reader” (KO’N, KF, DC) (appendix 2), 
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using pre-deﬁned technical (signal misalignment, leak, did not meet end of test criteria, N2 
did not return to baseline between trials) and qualitative (repeatable testing session which 
reﬂects tidal breathing) criteria (11). Troubleshooting teleconferences between over-readers 
in Belfast and 1-2 independent over-reader(s) from the Royal Brompton London convened 
monthly  to  discuss  and  compare  over-reading  practice  in  accordance  with  criteria. 
Questionable tests were assessed by the group and inter-rater agreement sought.  
To derive a LCI result, a minimum of 2 technically valid and repeatable trials which 
represented tidal breathing were required. Tests with 3 trials are required to calculate LCI ≥
CV%  and  VT  CV% in  accordance  with  analysis  guidelines  in  the  inert  gas  washout   
consensus statement (10). Values for LCI, LCI CV% and VT CV% before and after over- 
reading were recorded. Only those tests with a LCI value before and after over-reading (i.e. 
deemed to have a minimum of 2 technically valid and repeatable trials which represented 
tidal breathing) could be included in the comparison of LCI, LCI CV% and VT CV% before 
and after over-reading (i.e. those deemed not to meet this criteria either by the site or the 
over-reader did not have matching data). Only MBW tests with data before and after over-
reading were included in the subsequent analysis. Before analysis, the data underwent a 
data cleaning process, where all entries were checked against source data (original spx. 
MBW data ﬁle) for accuracy.  
Statistical  analyses  were  conducted  using  SPSS  version  22  (IBM  Corporation, 
Somers,  New  York,  USA).  As  the  database  contained  multiple  entries  from  individual 
patients, the mean ratio of LCI, LCI CV% and VT CV% values before and after over-reading 
was  calculated  for  analysis.  Mean  ratios  were  log  transformed  to  facilitate  analysis  and 
simple t-tests were performed on the log ratios to test the null hypothesis of no eﬀect i.e. no 
change in LCI,  LCI  CV% and VT CV% with over-reading. Sub group analysis of  logged 
mean ratios of LCI, LCI CV% and VT CV% were used to assess for diﬀerences based on 
expert MBW site vs. new MBW site; stable vs. exacerbation patient visit; length of site MBW 
testing activity (ﬁrst 12 vs. second 12 months), using independent samples t-test. A p value 
<0.05 was considered signiﬁcant.  Results are presented in raw values of LCI (number of 
turnovers), LCI CV% and VT CV%. 
 
Results:  
Patient data 
Data from 250 MBW tests collected from 98 patients over 5 UK sites were analysed in July 
2017. Mean (SD) age was 65.4 (10.8) years, 63 (63%) were female. For all patients, the 
aetiology  of  bronchiectasis  was  idiopathic  or  post  infectious.  The  database  contained 
between 1-6 visits per patient during clinical stability and at the start and end of the protocol 
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deﬁned pulmonary exacerbation, totalling 250 tests. Figure 1 presents steps of the over-
reading process and identiﬁes the MBW tests included in analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visits where subject 
unable to tolerate or 
complete the MBW test 
(n=10) 
Visits where MBW test 
completed 
(n=240) 
Visits with LCI result 
before and after over-
reading (i.e. included in 
analysis)  
n=210 
Visits with LCI CV% and 
VT CV% result before 
and after over-reading 
(i.e. included in 
analysis)  
n=151 
DATA SENT TO CENTRAL OVER-READER 
Visits with LCI result 
before and after over-
reading  
n=210 
Visits with LCI CV% and VT CV% 
result after over-reading (i.e.  3 ≥
trials) 
59/210 MBW tests were made 
up of 2 trials 
 
 
LCI LCI CV% 
Visits with LCI result 
before and after over-
reading  
n=210 
Visits where MBW 
attempted 
(n=250) 
 
MBW  tests  deemed 
unacceptable  for  analysis 
(n=30) 
 
Reasons:
 
Excluded  by  over-reader 
after over-reading 
n=23 
Technical  (signal 
synchronisation,  leak,  N2 
not  returned  to  baseline, 
end  of  tests  criteria  not 
met)  
n=2 
Qualitative  (not 
representative  of  tidal 
breathing, not repeatable)  
 
Excluded  by  the  site 
before over-reading: 
n=5 
MBW  tests  incorrectly 
excluded by site pre-over-
reading  i.e.  no  pre  over-
reading result 
 
Reasons:  Presumed 
technical  issues  by  the 
site. 
 
(Further detail in appendix 
3). 
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Figure 1: Flowchart identifying MBW tests across 5 sites to be included in analysis  
 
 
During  10/250  visits,  the  patient  was  unable  to  tolerate  the  test  long  enough  to  collect 
enough data. Of those 240 visits with data, 30/240 (12%) were deemed unacceptable for 
analysis. 25/30 were excluded by the over-reader after over-reading and 5/30 were excluded 
by the site before over-reading. Without over-reading, these data would have otherwise been 
incorrectly included or excluded in the database analysis (Table 1). The mean (SD) [range] 
LCI no. turnovers of the data included in the analysis was 13.1 (3.7) [7.4-23.3]. Mean (SD) 
[range] LCI CV% and VT CV% of the data included in the analysis was 3.7 (2.2) [0.4-10.0] 
and 5.8 (4.8) [0.7-27.4]. FEV1 data was available for  243/250 visits. Mean (SD) FEV1 % 
predicted  was  70.2  (20.6%),  range  25.6  to  126.0.  Considering  the  range  of  severity, 
FEV1>80% in 79/243 (32%), FEV1=50-80% in 120/243 (49%), FEV1=30-50% in 38/243 (16%) 
and FEV1<30% in 6/243 (2%). 
 
The n (%) of tests excluded or included post over reading across the categories of disease 
severity according to FEV1 were 8/40 (23) [FEV1>80%], 23/40 (58) [FEV1=50-80%], 4/40 (10) 
[FEV1=30-50%]. Five excluded tests did not have FEV1 data. Thirty-two patients accounted 
for the 40 tests excluded (25 patients had 1 test excluded, 6 patients had 2 tests excluded, 1 
patient had 3 tests excluded). Therefore, there was no indication that test exclusions were 
higher in patients with more severe disease or that a core group of patients were solely 
responsible for the tests excluded. 
 
The LCI CV% of those deemed unacceptable for analysis (30/240) was signiﬁcantly larger 
than the LCI CV% in the 210/240 tests suitable for analysis (mean [SD] CV% 7.9 [2.3] vs. 
2.7 [0.2] p=0.004). In total, 210 tests had LCI results which were suitable for subsequent 
analysis (matched data before and after over-reading). One hundred and ﬁfty one tests had 
3 or more trials and therefore had a LCI CV% and a VT CV% available for analysis.  
 The change in LCI, LCI CV% and VT CV% with over-reading in these tests was not 
statistically signiﬁcant (Table 1).  
The mean (SD) LCI CV% across the categories of disease severity according to FEV1 were 
3.5  (2.0)  [FEV1  >80%],  4.0  (2.3)  [FEV1=50-80%],  3.5  (2.2)  [FEV1=30-50%]  and  3.6  (1.7) 
[FEV1<30].  The mean (SD) VT CV% across the categories of disease severity according to 
FEV1 were 6.2 (5.2) [FEV1>80%], 5.7 (4.4) [FEV1=50-80%], 6.2 (6.0) [FEV1=30-50%] and 2.4 
(0.7)  [FEV1<30].  Therefore  there  was  no  pattern  between  the  variability  of  LCI  or  tidal 
breathing and disease severity.   
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Table 1:  Change in  LCI,  LCI  CV%  and VT CV% with  over-reading  in  each site and 
overall 
iteS  1 2 3 4 5 Overall  
N tests attempted  
N  patients  unable  to  tolerate  test 
therefore no data 
74  
 
2 
33 
 
0 
25  
 
2 
59 
 
5 
59  
 
1 
250 
 
10 
N with data 
N (%) test excluded after over-reading  
N (%) test included after over-reading  
72/74 
4 
2 
33/33 
6 
0 
23/25 
4 
0 
54/59 
9 
1 
58/59 
2 
2 
240/250 
25/240 (10%) 
5/240 (2%) 
Total excluded post over reading  6  6  4  10  4  30/240 (12%) 
N  tests  with  data  before  and  after  over 
reading  
66  27  19  44  54  210 
Mean  (SD)  LCI  [range]  (no.  turnovers) 
change with over-reading 
0.07 
(0.18) 
0.19 
(0.28) 
0.25 
(0.73) 
0.10 
(0.21) 
0.03  
(0.09) 
N=210 
0.10 (0.28)  
[0- 3.21] 
p=0.07 
Mean  (SD)  LCI  CV%  change  with over-
reading 
0.37 
(1.46) 
0.96 
(2.03) 
0.05 
(0.11) 
0.38 
(1.60) 
0.21 
(0.80) 
N=151 
0.35 (1.33) 
p=0.78 
Mean  (SD)  VT  CV%  change  with  over-
reading 
0.14 
(0.57) 
1.66 
(4.57) 
0.59 
(1.83) 
0.09 
(0.46) 
0 
(0) 
N=151 
0.25 (1.50) 
p=0.79 
CV%=  coeﬀicient  of  variation;  LCI=  lung  clearance  index;  N=number;  SD=standard 
deviation; VT= tidal volume 
 
In those tests analysed (n=210) the change in LCI with over reading was compared in MBW 
new sites vs. MBW expert sites. The mean change in LCI in sites who were new to MBW 
(mean [SD] {range} change=0.16 [0.39] {0 - 3.21} lung turnovers) was signiﬁcantly larger 
compared with MBW expert sites (mean [SD] {range} change= 0.05 [0.15] {0 – 1.02} lung 
turnovers)  (p=0.047).  The  change  in  LCI  CV%  (p=0.74)  or  VT  CV%  (p=0.46)  was  not 
signiﬁcant, comparing sites new to MBW vs. MBW expert sites.  
 The over-reading outcome from MBW tests from the ﬁrst 12 months of site MBW test 
activity compared to the remaining time period of MBW test activity (9 months), showed no 
diﬀerence LCI (p=0.23), LCI CV% (p=0.33) or VT CV% (p=0.51). The impact of the duration 
of current MBW activity on the change in LCI after over-reading, in new vs. expert sites was 
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also explored. In MBW new sites, change in LCI after over-reading were reduced to a level 
similar to that of MBW expert sites by 6 months (mean [SD] change=0.07 [0.14] vs. 0.02 
[0.05] lung turnovers), but increased again at 12 months (mean [SD] change=0.23 [0.60] vs. 
0.06 [0.18] lung turnovers), indicating that over-reading may be of beneﬁt to MBW new sites 
up to at least 12 months post initiation of MBW activity.  
There  was  no  diﬀerence  in the  change  in  LCI (p=0.85),  LCI CV%  (p=0.41)  or  VT  CV% 
(p=0.75)  after  over-reading  between  clinically  stable  and  pulmonary  exacerbation  MBW 
tests.  
 
Discussion 
This is the first study to assess the impact of central over-reading on MBN2W variables in a 
bronchiectasis multicentre  clinical  trial  setting,  including  patients across  the  range  of  the 
disease severity spectrum. We found that 12% of MBW tests were considered unacceptable 
after over-reading due to technical or quality issues. Without over-reading, these tests which 
had signiﬁcantly greater LCI variability (CV%), would have incorrectly been included in the 
database  for  analysis.  This  demonstrates  the  value  of  over-reading  to  both  avoid  the 
inclusion  of  invalid  data,  and  avoid  the  loss  of  valid  MBW  data.  For  those  MBW  tests 
included in the dataset, over-reading did not result in any change in LCI, LCI variability or VT 
variability values. However, sub-group analysis found that there was a signiﬁcant diﬀerence 
in the change in LCI after over-reading in sites new to MBW testing compared with those 
sites with MBW experience.  
Our data in BE is similar to those reported in CF (11), showing no group level change 
in the LCI value but a substantial proportion of tests excluded due to technical or qualitative 
issues. Our study had a lower proportion of tests excluded compared with Jensen et al (12% 
versus 27%). The larger proportion of tests excluded in Jensen et al may be explained by 
the  greater  incidence  of  quality  issues  relating  to  patient  non-cooperation  and  irregular 
breathing pattern seen in the paediatric age group during testing. In this study there was a 
strong emphasis on training and ongoing mentorship to the sites involved, with the support 
of an interactive e-learning tool (www.mbwtraining.com); given that the majority of sites were 
new to MBW. In addition, over-readers from the Belfast site were available via phone or 
email  to  answer  MBW  test  queries  in  real  time  and  provide  feedback  including  picture 
snapshots and a training point summary to resolve/avoid the quality issue. This may have 
helped to minimise the overall proportion of tests excluded. In addition to these findings, our 
study highlighted the importance of over-reading in sites new to MBW testing, demonstrating 
that over-reading improves accuracy of LCI results in these sites. Results from the study by 
Fuchs  et  al  also  found  that  operator  experience  inﬂuenced  MBW  test  success  rate  and 
indicated that it may improve with increasing study duration and experience with the test 
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procedure (18). Inclusion of a central over-reading process is resource intensive, with review 
of a single testing session requiring up to 1 hour including the completion of quality control 
logs  and  inter-rater  agreement.  Our  study results  may  support  a  pragmatic  approach  to 
central over-reading i.e. sites new to MBW testing should complete over-reading for at least 
a  12-month  duration.  The  degree  of  change  in  LCI  with  over-reading  was  small  (mean 
change  in  MBW  new  sites  =  0.16  lung  turnovers)  and  much  less  than  what  could  be 
considered a clinically meaningful change, as indicated in the CF literature (1.3 LCI lung 
turnovers; % change [95% limits]  =  1.27 [-25 to 27] (20,21). However, the range of  LCI 
change at an operator level (range of LCI change in MBW new sites= 0 – 3.21) suggests 
that impact of test quality could be larger within longitudinal studies or in studies measuring 
LCI treatment eﬀect.  
This  study  included  a  wide  range  of  disease  severity  but  we  found  no  pattern 
between disease severity and MBW test quality (number of tests excluded, LCI CV% or VT 
CV%). Whilst the proportion of patients in the severe disease category were small (2%) and 
further study of MBW outcomes in this category is required, this result also demonstrates the 
robust  nature  and clinical utility  of  LCI as  an outcome measure across  a  wide range  of 
bronchiectasis disease severity. 
Our results suggest that the level of MBW experience inﬂuences result accuracy but 
the definition of an “expert” MBW site is subjective. In this study, the “expert” sites had > 5 
years’ experience on site with MBW testing and were currently active as central over-reading 
sites. This included >2 staﬀ who were routinely involved in MBW testing and over-reading, 
with  regular  troubleshooting  discussions  and  interrater  agreement.  Clinical  Research 
Organisation consideration of site MBW experience could reduce set-up time and result in 
better  quality  data  for  clinical  trials.  Site  MBW  experience  is  determined  by  individual 
operators and can be aﬀected by staﬀ turnover. Where a site is impacted by staﬀ turnover it 
will take additional time re-accumulate experience, therefore consideration of this issue is 
important in assessing the feasibility of MBW at individual sites. 
The most common reason for test exclusion was for technical reasons (leak, N2 not 
returned to baseline, end of test criteria not met, signal misalignment). This highlights the 
key  areas  for ongoing  training  and mentorship in  order  to minimise  the number  of tests 
excluded due to these reasons (Table 2). In this study, fewer tests were excluded due to 
quality issues (reﬂective of tidal breathing pattern) however, this aspect has the potential to 
signiﬁcantly alter results as demonstrated by Jensen et al. Currently, determination of tidal 
breathing is a subjective assessment taking into account the total duration of the washout. 
Further  work  to  establish  quantitative  limits  for  breathing  pattern  may  enable  a  more 
objective and standardised assessment. A limitation of this study is that  findings are not 
directly applicable to other MBW devices and software.  
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Conclusions 
As MBW testing is being increasingly used in bronchiectasis research, including sites new to 
the testing method, there is a need to determine what quality control measures are required 
to ensure that the data collected is research quality. The results from this study emphasise 
that central over-reading is required in bronchiectasis studies, to avoid inclusion or exclusion 
of invalid tests in analysis. In this study, over-reading improved result accuracy in MBW new 
sites and data suggests that over-reading could be important up to at least 12 months post 
initiation of MBW activity. 
 
Table  2: Technical  issues that  result  in  test  exclusion  and key  training points  to  reduce 
occurrence (10,11) 
Technical issues  Key training points 
Leak  Patient: 
•  Fitting of mouthpiece and nose clip comfortably with a tight 
seal. 
•  Distraction with TV to promote relaxed breathing. 
 
Recognition of leak: 
•  Sudden spike in N2 signal. 
•  Deviation in N2, O2 or CO2 signals inconsistent with phase of 
breath. 
•  Sudden step change in volume trace. 
•  Rise in N2 signal early in expirogram.  
 
Action on recognition of leak: 
•  Stop trial. 
•  Check patient positioning, mouthpiece and nose clip. 
•  Check ﬁtting of patient interface components. 
•  Repeat  trial  after  patient  rest  and  when  N2  returned  to 
baseline. 
 
Did  not  meet  end 
of test criteria 
Recognition of successful end of test: 
•   3 breaths < 2.5% N≥ 2. 
•  All 3 breaths reﬂective of tidal breathing. 
 
N2  not  returned  to 
baseline 
Recognition of N2 not returned to baseline: 
•  End tidal N2 77%  at  start of ﬁrst  trial and  within  1.5%  of ≥
baseline on subsequent trials.  
 
Action on recognition of N2 not returned to baseline: 
•  Stop trial. 
•  Allow suﬃcient time between trials.  
 
Signal 
misalignment  
Recognition of signal misalignment: 
•  Spikes, deviation in N2 inconsistent with phase of breath. 
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Action on recognition of signal misalignment: 
•  Stop trial. 
•  Perform  flow,  gas  calibration  and  ﬂow  gas  signal 
synchronization calibration.  
•  Seek advice on re-run of tests.  
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Appendix 1: 
Quality control messages provided by Ecomedics Exhalyzer® D using Spiroware software 
version 3.1.6. 
 
 
 
MA
NU
SC
RI
PT
 
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
 
QC MESSAGE 
 
TECHNICAL 
 
QUALITATIVE 
(BREATHING 
PATTERN) 
 
MISCELLANEOUS 
(SETUP,  CALIBRATION, 
TROUBLESHOOTING) 
At least two trials needed         
BTPS  Correction  Flow 
Inspiration out of valid Range 
       
BTPS  Correction  Flow 
Expiration out of valid Range 
 
       
Channel Calibration skipped 
 
       
Flow Calibration skipped 
 
       
Inspiratory Flow too high 
 
       
LCI Coeﬃcient of Variation too 
high 
       
LCI Target not reached 
 
       
N2  Inspiration  Mean  out  of 
valid Range 
 
       
O2 Drift Correction out of valid 
Range 
 
       
O2 End Expiration too high 
 
       
Sample  Flow  out  of  valid 
Range 
 
       
Standard  versus  CO2  Cet  out 
of valid Range 
 
       
Standard  RQ  out  of  valid 
Range Standard Deviation 
 
       
Wrong DSR used         
X2 Transit Time Error         
KEY: QC – Quality control; BTPS – Barometric temperature, ambient pressure; LCI – Lung 
Clearance Index; RQ – Respiratory Quotient; DSR – Dead space reducer 
 
 
 
 
 
 
Appendix 2 
 
 
 
MA
NU
SC
RI
PT
 
CC
EP
 TE
D
A
ACCEPTED MANUSCRIPT
14 
 
Summary of over-reader training  
 Pre-requisites for training:
•  Certiﬁcate in MBW testing for CF and/or Bronchiectasis patients. 
•  >2 years’ experience in MBW testing.  
 
 Training:
1 day training with trained over-reader covering: 
•  Orientation and familiarisation with Spiroware. 
•  Orientation and familiarisation with pre-deﬁned criteria for trial validity and quality. 
•  Orientation  and  familiarisation  with  quality  control  and  results  excel  sheets  for 
recording over-reading activity.  
 
Key references and contacts: 
•  Jensen, R., Stanojevic, S., Klingel, M., Pizarro, M.E., Hall, G.L., Ramsey, K., Foong, 
R., Saunders, C., Robinson, P.D., Webster, H., Hardaker, K., Kane, M. & Ratjen, F. 
2016, "A Systematic Approach to Multiple Breath Nitrogen Washout Test Quality", 
PLoS ONE, vol. 11, no. 6, pp. e0157523. 
•  Key reference documents from the LCI over-reading centre at the Royal Brompton 
London and Imperial College London.  
•  Key  reference  documents  from  the  North  American  MBW  centre: 
http://lab.research.sickkids.ca/ratjen/mbw-centre/#1476992018777-85ea347c-b8d3. 
 
 Certification:
•  Review, analysis and submission of 20 MBW tests (provided by the North American 
MBW centre). 
•  Analyses and certification ( 80% agreement on over-reading outcome of test) issued ≥
by the North American MBW centre. 
 
 
 
 
 
 
 
Appendix 3 
Reasons for test exclusion  
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MBW tests deemed unacceptable for analysis (n=30) 
 
Reason N (%) 
Excluded  by  over-reader  after  over-
reading for technical reasons including: 
 
• Patient related leak 
• Signal misalignment  
• Test  did  not  meet  end  of  test 
criteria 
• Equipment related leak 
• Other: Problems with equipment 
 
Excluded  by  over-reader  after  over-
reading  for  qualitative  reasons 
including: 
 
• Irregular breathing pattern 
 
Excluded  by  site  pre-over-reading  i.e. 
no  pre  over-reading  result  due  to 
presumed  qualitative  and  technical 
issues including: 
 
• Irregular breathing pattern 
• Patient related leak 
 
 
 
 
12/30 (40) 
5/30 (17) 
3/30 (10) 
2/30 (7) 
1/30 (3) 
 
 
 
 
2/30 (7) 
 
 
 
 
 
4/30 (13) 
1/30 (3) 
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•  Lung Clearance Index is emerging as a potential endpoint in bronchiectasis  
 
•  Data quality control or “over-reading” avoids the inclusion of invalid data  
 
•  MBW experience inﬂuences result accuracy 
 
